Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
Cholangitis
CHOLANGITIS
NewsGroups unite to fight liver disease during PBC Awareness Month
Members of the primary biliary cholangitis (PBC) community have come together in September as part of PBC Awareness Month to build support and share…
CHOLANGITIS
NewsNew trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…
CHOLANGITIS
NewsBlood marker can predict liver function improvement in PBC
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…
CHOLANGITIS
NewsChemomab, FDA align on key aspects of nebokitug development
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
CHOLANGITIS
NewsPSC raises colorectal cancer risk even without IBD
People with primary sclerosing cholangitis (PSC) have a six times higher risk of cancer affecting the large intestine or rectum, and that risk remained…
CHOLANGITIS
NewsAdding Vitamin D boosts PBC treatment in clinical trial
Adding vitamin D to ursodeoxycholic acid (UDCA) treatment is superior to UDCA alone at reducing symptoms, liver damage markers, and liver scarring in previously untreated…
CHOLANGITIS
NewsLarge study finds risks of liver cancer low for certain PSC patients
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis (PSC) who do not have…
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver function and ease itching in…
CHOLANGITIS
NewsUmecrine raises $2.5M to advance trial testing golexanolone for PBC
Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…
Recent Posts
- Biliary atresia treatment AX-0810 faring well in early testing
- Clinical trial results support bepirovirsen for hepatitis B
- Vitamin D may help protect against liver damage in those with PBC: Study
- Think smoking only affects your lungs? Your liver would like a word.
- Low vitamin D in early pregnancy tied to ICP risk, if fetus is a girl